Clinical Trial Update: A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

This document reports an ongoing Phase 1/2 study evaluating tazemetostat with rituximab and abbreviated bendamustine as frontline therapy for high tumor burden …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• TAZVERIK (TAZEMETOSTAT)
• Treanda (Bendamustine)

Snippet

Sponsor: Vaishalee Kenkre | Conditions: Follicular Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING